It found that, of 107 responses, only 3% deemed that digital transformation would have no impact on the drug development timeline while ... driven drugs are in early stages suggests that more ...

The healthcare and medical industries are increasingly integrating artificial intelligence into their operations, ...

Commissioner Markary announced the plans alongside the results of a generative AI pilot for scientific reviewers.

Janssen has ended the troubled phase 3 development programme for its fulranumab osteoarthritis pain drug, deciding that it was no longer a priority. The Johnson & Johnson (J&J) unit said yesterday ...

AI promises to cut the cost and timeline. Standigm is one of the early pioneers to apply the power of AI technologies to drug discovery and development. The company hopes to eliminate some of the ...